Reactions Weekly

, Volume 1732, Issue 1, pp 296–296 | Cite as

Protein tyrosine kinase inhibitors

Drug resistance in lung adenocarcinoma: 4 case reports
Case report
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

A study of 30 patients described 4 patients (3 woman and 1 man), aged 47−69 years, who developed resistance to erlotinib, gefitinib, nazartinib [EGF816] or osimertinib while being treated for lung adenocarcinoma (LADC) [routes and outcomes not stated; not all dosages stated].

Patient 1: The 59-year-old woman, who had LADC, received erlotinib therapy for 22 months. She exhibited progression while receiving erlotinib, with detection of acquired epidermal growth factor receptor (EGFR)T790Mmutation (developed resistance to erlotinib, and erlotinib was stopped). She was then enrolled to a trial (AURA trial -NCT01802632), and subsequently started receiving osimertinib 80mg, once daily. Thereafter, a partial response was achieved. However 8.2 months later, a disease progression...


  1. Fassunke J, et al. Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nature Communications 9: 4655, No. 1, Dec 2018. Available from: URL: - GermanyCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations